ZIVO Bioscience Future Growth

Future criteria checks 2/6

ZIVO Bioscience is forecast to grow earnings and revenue by 58.7% and 160.8% per annum respectively while EPS is expected to grow by 92.1% per annum.

Key information

58.7%

Earnings growth rate

92.1%

EPS growth rate

Personal Products earnings growth	25.3%
Revenue growth rate	160.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	04 Jun 2024

Recent future growth updates

No updates

Recent updates

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Nov 25

Earnings and Revenue Growth Forecasts

OTCPK:ZIVO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	2	-5	N/A	N/A	1
12/31/2024	0	-6	N/A	N/A	1
6/30/2024	0	-13	-5	-5	N/A
3/31/2024	0	-7	-5	-5	N/A
12/31/2023	0	-8	-6	-6	N/A
9/30/2023	0	-9	-7	-7	N/A
6/30/2023	0	-9	-6	-6	N/A
3/31/2023	N/A	-9	-6	-6	N/A
12/31/2022	N/A	-9	-7	-7	N/A
9/30/2022	N/A	-9	-8	-8	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-9	-9	-9	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-9	-5	-5	N/A
3/31/2021	N/A	-9	-3	-3	N/A
12/31/2020	0	-9	-3	-3	N/A
9/30/2020	0	-11	-2	-2	N/A
6/30/2020	0	-10	-3	-3	N/A
3/31/2020	0	-11	-4	-4	N/A
12/31/2019	N/A	-12	-4	-4	N/A
9/30/2019	N/A	-10	-4	-4	N/A
6/30/2019	N/A	-13	-4	-4	N/A
3/31/2019	N/A	-14	-5	-5	N/A
12/31/2018	N/A	-15	-5	-5	N/A
9/30/2018	N/A	-15	-5	-5	N/A
6/30/2018	N/A	-14	-5	-5	N/A
3/31/2018	N/A	-12	N/A	-5	N/A
12/31/2017	N/A	-10	N/A	-4	N/A
9/30/2017	N/A	-7	N/A	-4	N/A
6/30/2017	N/A	-6	N/A	-3	N/A
3/31/2017	N/A	-7	N/A	-2	N/A
12/31/2016	N/A	-6	N/A	-3	N/A
9/30/2016	N/A	-6	N/A	-2	N/A
6/30/2016	N/A	-6	N/A	-2	N/A
3/31/2016	N/A	-6	N/A	-3	N/A
12/31/2015	N/A	-6	N/A	-2	N/A
9/30/2015	N/A	-4	N/A	-2	N/A
6/30/2015	N/A	-6	N/A	-3	N/A
3/31/2015	N/A	-5	N/A	-2	N/A
12/31/2014	N/A	1	N/A	-3	N/A
9/30/2014	N/A	0	N/A	-3	N/A
6/30/2014	N/A	-1	N/A	-3	N/A
3/31/2014	N/A	-5	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZIVO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZIVO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZIVO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZIVO's revenue (160.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ZIVO's revenue (160.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ZIVO's Return on Equity is forecast to be high in 3 years time

ZIVO Bioscience Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

ZIVO Bioscience, Inc. Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024

The Nasdaq Stock Market to Delist the Common Stock of ZIVO Bioscience

ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

New major risk - Share price stability

ZIVO Bioscience Announces Reverse Stock Split to Regain Compliance with the Nasdaq Stock Market’s Continued Listing Requirements

New major risk - Market cap size

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Nasdaq Hearings Panel Grants Zivo Biosciences's Request to Provide an Extension Until November 20, 2023 to Regain Compliance with the Stockholders’ Equity Rule for Continued Listing on Nasdaq

New minor risk - Shareholder dilution

Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient

Nasdaq Notifies Zivo Biosciences Regarding its Common Stock Delisting from Nasdaq Due to Non-Compliance with the Stockholders’ Equity Requirement

ZIVO Bioscience, Inc. Announces Results of Study with Its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Independent Director recently bought US$72k worth of stock

Zivo Bioscience Receives Written Notice from the Nasdaq Stock Market

ZIVO Bioscience, Inc. Reports USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

ZIVO Bioscience, Inc., Annual General Meeting, Jul 28, 2022

ZIVO Bioscience Regains Compliance Following Receipt of Non-Compliance Notice from Nasdaq

ZIVO Bioscience, Inc. announced delayed annual 10-K filing

Independent Director recently bought US$340k worth of stock

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Independent Director Robert Rondeau has left the company

ZIVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $13.8 million.

ZIVO Bioscience, Inc. Announces Us Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health

ZIVO Bioscience, Inc. Appoints Alison A. Cornell as Member of the Board

ZIVO Bioscience, Inc. Announces Executive Changes

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies